Basis of Presentation and Significant Accounting Policies - Additional Information (Details) $ / shares in Units, $ in Millions |
3 Months Ended |
|---|---|
|
Mar. 31, 2026
USD ($)
$ / shares
| |
| Indefinite-Lived Intangible Assets [Line Items] | |
| Exercise price | $ / shares | $ 0.001 |
| Federal research and development tax credits | $ 9.0 |
| Pre-2018 Federal | |
| Indefinite-Lived Intangible Assets [Line Items] | |
| Net operating loss | 62.6 |
| State | |
| Indefinite-Lived Intangible Assets [Line Items] | |
| Net operating loss | $ 230.2 |
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The net amount of research and development costs incurred for a fixed-price, best-efforts research and development cost-sharing arrangement with the Federal Government. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|